Antibody-Drug Conjugate

With more than 50 scientists, ChemPartner has a top-tier ADC team spanning multiple areas, such as antibody development, medicinal chemistry, DMPK and in vivo pharmacology. In addition to individual function service packages, ChemPartner also provides All-in-One ADC development service package from antibody generation to IND filing.

Our scientists are highly skilled in the design and synthesis of a variety of toxins and linkers, such as the mechanistically diverse MMAE/MMAF, Maytansine derivatives, Duocarmycin, Nemorubicin, and pyrrolobenzodiazepines. We purify and characterize ADCs using state-of-the-art technologies. A dedicated, certified, high-potency lab is fully operational and capable of handling APIs with OEL < 1 ug/m3 at scale up to 50 grams.

Our biologics team is able to develop antibodoes from scratch using Phage display or Hybridoma methods. The CMC team has GMP compliance antibody production and fill-finish capacity up to 400 grams. The ADC team has early discovery, optimization, and evaluation capacity using different antibody, linker, and toxin combinations. The GLP CMC facility has the production capacity for producing up to 40 grams.

All ADC-related functions and developments are fully supported with a well-equipped, state-of-the-art analytical facility. The ADC team has also worked with many pharma and biotech companies on novel toxins to create novel ADCs with additional mechanisms of action.

Flexible Early Clinical Development

Antibody development from antigen generation until humanized antibody production cell line generation
Customized toxin/linker design and synthesis
Preparation of ADC sample panels using a variety of linker/toxin/mAb combinations
ADC scale-up process development and formulation development
Dedicated ADC R&D teams ready for new projects and drop-ins
GLP ADC production up to 40 grams
DMPK and in vivo pharmacology team support IND-enabling test